Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-label, Multicenter Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Subjects With Non-transfusion-dependent Thalassemia

Next Previous
X
Search
Trial Profile

A Phase 2, Open-label, Multicenter Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Subjects With Non-transfusion-dependent Thalassemia

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mitapivat (Primary)
  • Indications Alpha-thalassaemia; Beta-thalassaemia; Thalassaemia
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Agios Pharmaceuticals

    • Most Recent Events

    • 13 Dec 2022 Results assessing the effect of mitapivat on markers of erythropoietic activity through Week 72, along with Hb and markers of hemolysis and iron homeostasis, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
    • 10 Dec 2022 According to an Agios Pharmaceuticals media release, the company will host a live investor event o review the key clinical oral and poster presentations from this year ASH meeting.
    • 10 Dec 2022 According to an Agios Pharmaceuticals media release, data from the study were presented in a poster presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top